US FDA advises an alternative to Innohep in certain older patients
This article was originally published in Scrip
Executive Summary
The US FDAis advising healthcare professionals to use alternative treatments to Innohep (tinzaparin) in certain patients over 70 years of age, following a review of the Innohep in Renal Insufficiency Study (IRIS). The European IRIS study was stopped in February 2008 by its data safety monitoring committee because of an interim finding of an increase in all-cause mortality in patients who received the low molecular weight heparin.